Asset Details
Do you wish to reserve the book?
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury
Do you wish to request the book?
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury
2021
Overview
Recent studies suggested that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, developed for the treatment of chronic lymphocytic leukemia, may prevent NLRP3 inflammasome activation in macrophages, IL-1β secretion and subsequent development of inflammation and organ fibrosis. The role of NLRP3 has been underlined in the various causes of acute kidney injury (AKI), a pathology characterized by high morbimortality and risk of transition toward chronic kidney disease (CKD). We therefore hypothesized that the BTK-inhibitor ibrutinib could be a candidate drug for AKI treatment. Here, we observed in both an AKI model (glycerol-induced rhabdomyolysis) and a model of rapidly progressive kidney fibrosis (unilateral ureteral obstruction), that ibrutinib did not prevent inflammatory cell recruitment in the kidney and fibrosis. Moreover, ibrutinib pre-exposure led to high mortality rate owing to severer rhabdomyolysis and AKI. In vitro, ibrutinib potentiated or had no effect on the secretion of IL-1β by monocytes exposed to uromodulin or myoglobin, two danger-associated molecule patterns proteins involved in the AKI to CKD transition. According to these results, ibrutinib should not be considered a candidate drug for patients developing AKI.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/4022
/ Acute Kidney Injury - chemically induced
/ Acute Kidney Injury - complications
/ Adenine - analogs & derivatives
/ Agammaglobulinaemia Tyrosine Kinase - metabolism
/ Animals
/ Antineoplastic Agents - pharmacology
/ Chronic lymphocytic leukemia
/ Fibrosis
/ Fibrosis - prevention & control
/ Glycerol
/ Humanities and Social Sciences
/ Humans
/ IL-1β
/ Kidney
/ Kidneys
/ Leukemia
/ Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
/ Male
/ Mice
/ Protein Kinase Inhibitors - metabolism
/ Rhabdomyolysis - complications
/ Science
